Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Nestor, Avgoustidis"'
Autor:
Alessandra Bortoluzzi, Marcello Govoni, Prodromos Sidiropoulos, George Bertsias, Konstantinos Parperis, Argyro Repa, Dimitrios Boumpas, Ettore Silvagni, Myrto Nikoloudaki, Nestor Avgoustidis, Panagiotis Garantziotis, Sofia Pitsigavdaki, Antonio Marangoni, Irini Flouri
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/1d06bdf952c84ffc8770dbe43eff47ce
Autor:
Prodromos Sidiropoulos, George Bertsias, Argyro Repa, Eleni Kalogiannaki, Antonios Bertsias, Nestor Avgoustidis, Sofia Pitsigavdaki, Irini D Flouri
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Background Characterisation of the long-term outcome of patients with ‘difficult to treat’ (D2T) rheumatoid arthritis and factors contributing to its evolution are unknown. Herein, we explored the heterogeneity and contributing factors of D2T lon
Externí odkaz:
https://doaj.org/article/0f0a233a74b046ee84838cb7722bcc8b
Autor:
Antonios Bertsias, Nestor Avgoustidis, Ioannis Papalopoulos, Argyro Repa, Nikolaos Kougkas, Eleni Kalogiannaki, Georgios Bertsias, Irini Flouri, Prodromos Sidiropoulos
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Rituximab is used for the treatment of active rheumatoid arthritis. In the present study, we examined the long-term flare risk and safety of reduced doses of rituximab. Patients-methods This was a prospective, observational, singl
Externí odkaz:
https://doaj.org/article/f0dfe4ef435643669d190c76013bb7d5
Autor:
Panagiota Goutakoli, Garyfalia Papadaki, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Irini Flouri, Antonios Bertsias, Jerome Zoidakis, Martina Samiotaki, George Bertsias, Maria Semitekolou, Panayotis Verginis, Prodromos Sidiropoulos
Publikováno v:
Cells, Vol 12, Iss 24, p 2808 (2023)
Abatacept (CTLA4-Ig)—a monoclonal antibody which restricts T cell activation—is an effective treatment for rheumatoid arthritis (RA). Nevertheless, only 50% of RA patients attain clinical responses, while predictors of response are rather limited
Externí odkaz:
https://doaj.org/article/a6981a7ead1247d6a980be087c5c8d93
Autor:
Nestor Avgoustidis, Nikolaos Kougkas, Elias Drakos, Ioannis Galanakis, Katerina Pateromichelaki, Sofia Pitsigavdaki, Ioannis Papalopoulos, Argyro Repa, Prodromos Sidiropoulos
Publikováno v:
Bone Reports, Vol 13, Iss , Pp 100585- (2020)
Externí odkaz:
https://doaj.org/article/9190f6cc321e4dadbd6e5d8410368cd7
Autor:
Ricard Cervera, Marcello Govoni, Alberto Cauli, Matteo Piga, Alberto Floris, Mattia Congia, Alessandro Mathieu, Florenzo Iannone, George Bertsias, Luca Cantarini, Vincenzo Venerito, Giuseppe Lopalco, Antonio Vitale, Piergiorgio Neri, Carlos Vasconcelos, Raquel Faria, Gerard Espinosa, Elisabetta Chessa, Ignasi Rodriguez Pinto, Andrea Lo Monaco, GIOVANNI CIANCIO, Luísa Serpa Pinto, Nikolaos Kougkas, Ida Orlando, Vittorio Pirani, Ernestina Santos, João Correia, Ana Martins Silva, Monica Muntoni, Nestor Avgoustidis, Roberto Rios Garcés, Giulio Guerrini, Gema Lledó Ibáñez, Piero Mascia
Publikováno v:
RMD Open, Vol 6, Iss 2 (2020)
Objective To develop and validate the evidence-based and consensus-based Behçet’s Syndrome Overall Damage Index (BODI).Methods Starting from 120 literature-retrieved preliminary items, the BODI underwent multiple Delphi rounds with an internationa
Externí odkaz:
https://doaj.org/article/86a4379847224c1fbe859c2869e3c73f
Autor:
Georgia Dimitraki, Emmanouil Papastefanakis, Georgia Ktistaki, Antonis Fanouriakis, Christina Adamichou, Nikolaos Kougkas, Argyro Repa, Nestor Avgoustidis, George Bertsias, Prodromos Sidiropoulos, Alexandros N. Vgontzas, Panagiotis G. Simos, Evangelos C. Karademas
Publikováno v:
Current Psychology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae7b494989e39233d043d65824fd0e31
https://doi.org/10.1007/s12144-022-02937-y
https://doi.org/10.1007/s12144-022-02937-y
Autor:
Antonios Bertsias, Nestor Avgoustidis, Ioannis Papalopoulos, Argyro Repa, Nikolaos Kougkas, Eleni Kalogiannaki, Georgios Bertsias, Irini Flouri, Prodromos Sidiropoulos
Publikováno v:
Arthritis researchtherapy. 24(1)
Background Rituximab is used for the treatment of active rheumatoid arthritis. In the present study, we examined the long-term flare risk and safety of reduced doses of rituximab. Patients-methods This was a prospective, observational, single-center
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba802b5d8246370d530645a242987211
https://pubmed.ncbi.nlm.nih.gov/35655317
https://pubmed.ncbi.nlm.nih.gov/35655317
Publikováno v:
Open Medicine, Vol 5, Iss 1, Pp 62-64 (2010)
Externí odkaz:
https://doaj.org/article/29bacf6fcea8439db3f8dfda9c9d8e24
Autor:
George Bertsias, Ioannis Papalopoulos, Argiro Repa, Nestor Avgoustidis, Nikolaos Kougkas, Prodromos Sidiropoulos
Publikováno v:
Rheumatology international. 41(10)
RTX could be an effective and safe alternative treatment for refractory EF. Rituximab (RTX) is a successful therapeutic option for various autoimmune diseases. Our aim is to report our experience with RTX in eosinophilic fasciitis (EF) and review pub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14579f6cdaa238d118720c23d2e22adc
https://pubmed.ncbi.nlm.nih.gov/34009397
https://pubmed.ncbi.nlm.nih.gov/34009397